Implications of HIV treatment advances for behavioral research on AIDS: Protease inhibitors and new challenges in HIV secondary prevention

Health Psychology

Volumn 17, Issue 4, 1998, Pages 310-319

  Kelly, Jeffrey A ^a   Otto Salaj, Laura L ^a   Sikkema, Kathleen J ^a   Pinkerton, Steven D ^a   Bloom, Frederick R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adherence; AIDS; HIV; Risk behavior; Secondary prevention

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BEHAVIOR; COMBINATION CHEMOTHERAPY; COPING BEHAVIOR; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; VIRUS LOAD;

EID: 0031820161     PISSN: 02786133     EISSN: None     Source Type: Journal    
DOI: 10.1037/0278-6133.17.4.310     Document Type: Review

References (5)

1. Andersen, D. J., O'Brien, T. R., Politch, J. A., Martinez, A., Seage, G. R., Padian, N., Horsburgh, C. R., & Mayer, K. H. (1992). Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency vims type 1 in semen. Journal of the American Medical Association, 267, 2769-2774.
2. Angarano, G., Monno, L., Arpice, A., Gianelli, A., Romanelli, C., Fico, C., & Pastori, G. (1994). Transmission of zidovudine resistant HIV-1 through heterosexual contacts. AIDS, 8, 1013-1014.
3. Bangsberg, D., Tulsky, J. P., Hecht, F. M., & Moss, A. R. (1997). Protease inhibitors in the homeless. Journal of the American Medical Association, 278, 63-65.
4. Becker, M. H., & Maiman, L. A. (1980). Strategies for enhancing patient compliance. Journal of Community Health, 6, 113-115.
5. 3. Paper presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada.